Target Name: CCNDBP1
NCBI ID: G23582
Other Name(s): Cyclin D1 binding protein 1, transcript variant 1 | Grap2 cyclin interacting protein | HHM Protein | cyclin D-type binding-protein 1 | Human homolog of Maid | cyclin D1 binding protein 1 | Cyclin-D1-binding protein 1 | GCIP | HHM | DIP1 | D-type cyclin-interacting protein 1 | grap2 and cyclin-D-interacting protein | MAID protein | human homolog of Maid | CCNDBP1 variant 1 | Grap2 and cyclin-D-interacting protein | CCDB1_HUMAN

Cyclin D1 Binding Protein 1 (CCNDBP1): A Potential Drug Target and Biomarker

Introduction

Cyclin D1 (CDK1) is a key regulator of cell cycle progression and growth, which is essential for proper development, wound healing, and tissue regeneration. CDK1 has four isoforms, D1, D2, D3, and D4, that are involved in different stages of cell cycle progression. D1 is the most abundant and widely expressed isoform, and it plays a crucial role in regulating cell growth and the transition from the G1 phase to the S phase. CDK1 has been implicated in various diseases, including cancer, neurodegenerative diseases , and developmental disorders.

The Cyclin D1 Binding Protein 1 (CCNDBP1) is a protein that is primarily expressed in the brain and is known to interact with CDK1. CCNDBP1 functions as a negative regulator of CDK1, which means that it prevents the activity of CDK1 and inhibits its ability to bind to DNA. This interaction between CDK1 and CCNDBP1 is crucial for the regulation of cell cycle progression and growth.

Drug Target and Biomarker

The potential drug targets for CCNDBP1 are numerous and range from cancer therapies to neurodegenerative diseases. One of the primary drug targets for CCNDBP1 is the treatment of cancer, where abnormal expression of CDK1 has been observed in many types of cancer. For instance, it has has been reported that CDK1 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancers. Therefore, inhibiting the activity of CDK1 and promoting its downregulation could be a promising strategy for cancer treatment.

Another potential drug target for CCNDBP1 is the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be caused by the misfolded proteins, including CDK1. Therefore, targeting CCNDBP1 could be a strategy to treat neurodegenerative diseases.

CCNDBP1 has also been suggested as a potential biomarker for various diseases, including cancer and neurodegenerative diseases. The expression of CCNDBP1 is known to be downregulated in various types of cancer, including breast, ovarian, and prostate cancers. Therefore, the levels of CCNDBP1 could be used as a biomarker for cancer diagnosis and monitoring. Similarly, the misfolded proteins, including CDK1, have been implicated in the development and progression of neurodegenerative diseases. Therefore, measuring the levels of CCNDBP1 could be a potential biomarker for neurodegenerative diseases.

Conclusion

In conclusion, CCNDBP1 is a protein that has significant implications for the regulation of cell cycle progression and growth. Its interaction with CDK1 and its role as a negative regulator of CDK1 make it a promising target for drug development in various diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the role of CCNDBP1 in disease progression and to develop effective therapies that target this protein.

Protein Name: Cyclin D1 Binding Protein 1

Functions: May negatively regulate cell cycle progression. May act at least in part via inhibition of the cyclin-D1/CDK4 complex, thereby preventing phosphorylation of RB1 and blocking E2F-dependent transcription

More Common Targets

CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex)